Prelude Operating Income vs Cost Of Revenue Analysis

PRLD Stock

USD 0.98 0.02 2.08%

Prelude Therapeutics financial indicator trend analysis is much more than just breaking down Prelude Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Prelude Therapeutics is a good investment. Please check the relationship between Prelude Therapeutics Operating Income and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Prelude Therapeutics Operating Income account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Prelude Therapeutics' Operating Income and Cost Of Revenue is -0.86. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Prelude Therapeutics, assuming nothing else is changed. The correlation between historical values of Prelude Therapeutics' Operating Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Prelude Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Operating Income i.e., Prelude Therapeutics' Operating Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.86

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Prelude Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Prelude Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Prelude Therapeutics income statement and represents the costs associated with goods and services Prelude Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Prelude Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 124.1 M, whereas Selling General Administrative is forecasted to decline to about 18.9 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	915K	1.3M	1.2M	827.2K
Total Operating Expenses	113.7M	123.5M	132.3M	86.4M

Reconciled Depreciation Total Operating Expenses

Prelude Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital	Property Plant Equipment	Short Long Term Debt Total	Other Current Assets	Short Term Debt
Total Assets		0.93	0.96	1.0	0.85	0.99	0.61	-0.35	-0.84	0.94	0.44	0.69	1.0	0.94	-0.82	0.87	-0.61	1.0	0.6	1.0	0.86	1.0	0.88	0.59	0.85	0.97
Other Current Liab	0.93		0.97	0.91	0.88	0.9	0.73	-0.22	-0.93	0.85	0.33	0.8	0.91	0.98	-0.72	0.9	-0.42	0.91	0.72	0.91	0.87	0.9	0.93	0.71	0.6	0.91
Total Current Liabilities	0.96	0.97		0.94	0.92	0.94	0.66	-0.16	-0.91	0.94	0.26	0.75	0.94	0.95	-0.75	0.92	-0.47	0.94	0.65	0.94	0.93	0.93	0.94	0.63	0.7	0.94
Total Stockholder Equity	1.0	0.91	0.94		0.82	1.0	0.57	-0.39	-0.81	0.93	0.48	0.65	1.0	0.92	-0.86	0.85	-0.68	1.0	0.56	1.0	0.83	1.0	0.85	0.56	0.86	0.98
Other Liab	0.85	0.88	0.92	0.82		0.8	0.81	0.15	-0.96	0.86	-0.01	0.88	0.82	0.9	-0.62	0.99	-0.38	0.82	0.8	0.82	1.0	0.81	0.98	0.77	0.62	0.81
Net Tangible Assets	0.99	0.9	0.94	1.0	0.8		0.54	-0.4	-0.78	0.93	0.49	0.62	1.0	0.91	-0.87	0.83	-0.69	1.0	0.53	1.0	0.82	1.0	0.83	0.52	0.86	0.98
Property Plant And Equipment Net	0.61	0.73	0.66	0.57	0.81	0.54		0.14	-0.89	0.47	0.04	0.99	0.57	0.8	-0.36	0.85	-0.15	0.57	1.0	0.57	0.75	0.56	0.84	1.0	0.33	0.55
Net Debt	-0.35	-0.22	-0.16	-0.39	0.15	-0.4	0.14		-0.03	-0.2	-0.98	0.14	-0.39	-0.18	0.51	0.06	0.55	-0.39	0.14	-0.39	0.14	-0.4	0.01	0.11	-0.43	-0.45
Retained Earnings	-0.84	-0.93	-0.91	-0.81	-0.96	-0.78	-0.89	-0.03		-0.78	-0.13	-0.95	-0.81	-0.94	0.61	-0.98	0.34	-0.81	-0.89	-0.81	-0.94	-0.8	-0.99	-0.87	-0.52	-0.82
Accounts Payable	0.94	0.85	0.94	0.93	0.86	0.93	0.47	-0.2	-0.78		0.27	0.58	0.94	0.83	-0.76	0.84	-0.57	0.93	0.46	0.94	0.89	0.94	0.86	0.44	0.84	0.93
Cash	0.44	0.33	0.26	0.48	-0.01	0.49	0.04	-0.98	-0.13	0.27		0.04	0.48	0.3	-0.58	0.09	-0.59	0.48	0.04	0.48	-0.01	0.49	0.14	0.07	0.49	0.54
Non Current Assets Total	0.69	0.8	0.75	0.65	0.88	0.62	0.99	0.14	-0.95	0.58	0.04		0.65	0.86	-0.45	0.92	-0.21	0.65	0.98	0.65	0.84	0.64	0.91	0.98	0.38	0.64
Cash And Short Term Investments	1.0	0.91	0.94	1.0	0.82	1.0	0.57	-0.39	-0.81	0.94	0.48	0.65		0.91	-0.84	0.84	-0.65	1.0	0.56	1.0	0.84	1.0	0.86	0.55	0.88	0.98
Common Stock Shares Outstanding	0.94	0.98	0.95	0.92	0.9	0.91	0.8	-0.18	-0.94	0.83	0.3	0.86	0.91		-0.72	0.93	-0.45	0.92	0.8	0.91	0.89	0.91	0.94	0.79	0.64	0.89
Non Current Liabilities Total	-0.82	-0.72	-0.75	-0.86	-0.62	-0.87	-0.36	0.51	0.61	-0.76	-0.58	-0.45	-0.84	-0.72		-0.67	0.93	-0.86	-0.36	-0.83	-0.64	-0.84	-0.65	-0.36	-0.71	-0.88
Other Stockholder Equity	0.87	0.9	0.92	0.85	0.99	0.83	0.85	0.06	-0.98	0.84	0.09	0.92	0.84	0.93	-0.67		-0.44	0.85	0.85	0.84	0.98	0.83	0.99	0.83	0.62	0.84
Total Liab	-0.61	-0.42	-0.47	-0.68	-0.38	-0.69	-0.15	0.55	0.34	-0.57	-0.59	-0.21	-0.65	-0.45	0.93	-0.44		-0.68	-0.14	-0.64	-0.4	-0.65	-0.38	-0.15	-0.68	-0.68
Net Invested Capital	1.0	0.91	0.94	1.0	0.82	1.0	0.57	-0.39	-0.81	0.93	0.48	0.65	1.0	0.92	-0.86	0.85	-0.68		0.56	1.0	0.83	1.0	0.85	0.56	0.86	0.98
Property Plant And Equipment Gross	0.6	0.72	0.65	0.56	0.8	0.53	1.0	0.14	-0.89	0.46	0.04	0.98	0.56	0.8	-0.36	0.85	-0.14	0.56		0.56	0.75	0.55	0.83	1.0	0.32	0.55
Total Current Assets	1.0	0.91	0.94	1.0	0.82	1.0	0.57	-0.39	-0.81	0.94	0.48	0.65	1.0	0.91	-0.83	0.84	-0.64	1.0	0.56		0.84	1.0	0.86	0.55	0.88	0.98
Non Current Liabilities Other	0.86	0.87	0.93	0.83	1.0	0.82	0.75	0.14	-0.94	0.89	-0.01	0.84	0.84	0.89	-0.64	0.98	-0.4	0.83	0.75	0.84		0.83	0.97	0.72	0.64	0.82
Net Working Capital	1.0	0.9	0.93	1.0	0.81	1.0	0.56	-0.4	-0.8	0.94	0.49	0.64	1.0	0.91	-0.84	0.83	-0.65	1.0	0.55	1.0	0.83		0.85	0.54	0.89	0.98
Property Plant Equipment	0.88	0.93	0.94	0.85	0.98	0.83	0.84	0.01	-0.99	0.86	0.14	0.91	0.86	0.94	-0.65	0.99	-0.38	0.85	0.83	0.86	0.97	0.85		0.81	0.62	0.86
Short Long Term Debt Total	0.59	0.71	0.63	0.56	0.77	0.52	1.0	0.11	-0.87	0.44	0.07	0.98	0.55	0.79	-0.36	0.83	-0.15	0.56	1.0	0.55	0.72	0.54	0.81		0.32	0.54
Other Current Assets	0.85	0.6	0.7	0.86	0.62	0.86	0.33	-0.43	-0.52	0.84	0.49	0.38	0.88	0.64	-0.71	0.62	-0.68	0.86	0.32	0.88	0.64	0.89	0.62	0.32		0.82
Short Term Debt	0.97	0.91	0.94	0.98	0.81	0.98	0.55	-0.45	-0.82	0.93	0.54	0.64	0.98	0.89	-0.88	0.84	-0.68	0.98	0.55	0.98	0.82	0.98	0.86	0.54	0.82

Click cells to compare fundamentals

Prelude Therapeutics Account Relationship Matchups

Prelude Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.9M	223.6M	305.1M	220.5M	277.7M	195.3M
Other Current Liab	2.6M	7.5M	7.9M	11.3M	14.3M	8.2M
Total Current Liabilities	4.8M	11.4M	19.2M	21.7M	21.8M	14.9M
Total Stockholder Equity	(49.4M)	212.2M	285.9M	195.4M	237.1M	157.4M
Net Tangible Assets	(49.4M)	212.2M	285.9M	195.4M	224.8M	136.7M
Property Plant And Equipment Net	1.6M	2.5M	5.6M	6.7M	37.7M	39.6M
Net Debt	(18.6M)	(218.3M)	(30.1M)	(28.8M)	(8.4M)	(8.8M)
Retained Earnings	(50.5M)	(107.4M)	(219.1M)	(334.6M)	(456.4M)	(433.6M)
Accounts Payable	2.0M	3.9M	7.8M	6.8M	4.6M	4.8M
Cash	18.9M	218.3M	31.8M	30.6M	25.3M	45.4M
Non Current Assets Total	1.6M	2.8M	10.0M	16.1M	42.1M	44.2M
Cash And Short Term Investments	18.9M	218.3M	291.2M	201.7M	232.9M	179.4M
Common Stock Shares Outstanding	32.4M	43.7M	47.6M	47.4M	60.4M	48.3M
Liabilities And Stockholders Equity	21.9M	223.6M	305.1M	220.5M	277.7M	195.3M
Non Current Liabilities Total	66.4M	32K	9.6M	3.4M	18.7M	18.0M
Other Stockholder Equity	(65.4M)	96.0M	505.7M	531.7M	693.3M	727.9M
Total Liab	71.3M	11.4M	19.2M	25.1M	40.6M	27.6M
Net Invested Capital	(49.4M)	212.2M	285.9M	195.4M	237.1M	157.4M
Property Plant And Equipment Gross	1.6M	2.5M	5.6M	6.7M	41.3M	43.4M
Total Current Assets	20.2M	220.8M	295.1M	204.4M	235.6M	181.8M
Accumulated Other Comprehensive Income	(556K)	(223.6M)	(711K)	(1.7M)	223K	234.2K
Net Working Capital	15.4M	209.4M	275.9M	182.7M	213.8M	166.9M
Property Plant Equipment	1.6M	2.5M	5.6M	6.7M	7.7M	8.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:

How To Invest In Prelude

Details

Is Prelude Stock a good investment?

Details

What is Prelude Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.77)

Revenue Per Share

0.04

Return On Assets

(0.39)

Return On Equity

(0.67)

The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Prelude Operating Income vs Cost Of Revenue Analysis

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Cost Of Revenue

Prelude Therapeutics fundamental ratios Correlations

Prelude Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Prelude Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity

Property Plant Equipment	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.96	Other Liab
Non Current Assets Total	- 0.95	Retained Earnings
Non Current Liabilities Other	- 0.94	Retained Earnings